Navigating new opportunities in the IL-2 space
Continuing our cytokine series, we now switch horses from a creative new therapeutic utilising red blood cells that Rubius Therapeutics are pioneering to a very different technology involving synthetic amino acids, in what is known as a ‘Not Alpha’ IL–2 approach from Synthorx.
We have covered new developments in IL–2 based cytokines from Roche and Nektar previously, so what’s cool about the alternative early development that is THOR–707?
To find out, we conducted an expert interview with Synthorx’s Dr Laura Shawver and learned some fascinating details about their novel platform that is sending new molecules into the clinic in the very near future.
To learn more and get a heads up on our latest oncology insights and thought leader interviews, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
In the past, much of the focus at previous American Society of Hematology (ASH) meetings in this area has focused on the myriad of chemotherapy regimens and dose/schedule optimisations that followed in trying to boost patient outcomes.